Lunit루닛

Lunit's revenue is growing quickly, but losses remain very large relative to sales.

Lunit, a Korean medical AI company focused on cancer imaging, reported trailing twelve-month revenue of ₩91.8B through H1 2026, but operating losses of ₩70.2B mean it is far from profitable. The share price closed at ₩11,300 on 2026-10-23, down 42.6% over one year although up 15.2% over one month, and it trades well below its 52-week high of about ₩24,930.

What stands out

• Revenue rose from ₩13.9B in 2022 to ₩83.1B in 2025, with 53.4% growth in 2025, but operating margin was -100% in 2025 and -76.4% on a trailing basis.
• Trailing free cash flow was -₩53.3B, and cash of ₩154.5B against borrowings of ₩91.8B gives a net cash position in the data.
• Price-to-sales is 9.2 and price-to-book is 2.5, while P/E is not meaningful because earnings are negative; the dividend yield is 0%.
• Foreign ownership fell from 12.9% to 7.7% over about 60 days, and foreign investors were net sellers of about ₩20.7B over the last 20 days, while institutions were net buyers of about ₩15.0B.
• Recent filings are mainly convertible bond acquisitions and conversion price adjustments, plus stock purchase option grants; no recent news headlines are included in the data.

What to watch

• The next half-year or annual results, to see whether losses narrow as revenue grows.
• Further convertible bond filings and conversion price adjustments, which may affect share count and dilution.
• Foreign ownership and flow trends, given the recent net selling; the data does not include analyst views or forecasts.